Who
Mark Stenhouse
Director
Company insider
Files Form 4 as: Director, Phathom Pharmaceuticals; Chief Operating Officer, Prometheus Biosciences; President, Cologuard, Exact Sciences.
In numbers
- Trades disclosed
- 40
- Buys
- 1
- Sells
- 3
- Bought
- $266K
- Sold
- $1.8M
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 2 Apr 2018
- Last trade
- 19 May 2026
- Last filed
- 21 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 May 2026filed 21 May 2026 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —24,122 at $0.00 | filing |
| 19 May 2026filed 21 May 2026 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —24,122 at $0.00 | filing |
| 3 Jun 2025filed 5 Jun 2025 | PHAT Phathom Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,500 at $0.00 | filing |
| 3 Jun 2025filed 5 Jun 2025 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —10,500 at $0.00 | filing |
| 23 May 2024filed 24 May 2024 | PHAT Phathom Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,500 at $0.00 | filing |
| 23 May 2024filed 24 May 2024 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —10,500 at $0.00 | filing |
| 16 Jun 2023filed 16 Jun 2023 | Prometheus Biosciencesoption or derivative | SEC FORM 4 Code D | —40,000 | filing |
| 16 Jun 2023filed 16 Jun 2023 | Prometheus Biosciencesoption or derivative | SEC FORM 4 Code D | —240,000 | filing |
| 16 Jun 2023filed 16 Jun 2023 | Prometheus Biosciencesoption or derivative | SEC FORM 4 Code D | —70,371 | filing |
| 16 Jun 2023filed 16 Jun 2023 | Prometheus Biosciencesoption or derivative | SEC FORM 4 Code D | —86,582 | filing |
| 16 Jun 2023filed 16 Jun 2023 | Prometheus Biosciencesoption or derivative | SEC FORM 4 Code D | —34,085 | filing |
| 16 Jun 2023filed 16 Jun 2023 | Prometheus Biosciences | SEC FORM 4 Code D | —12,754 | filing |
| 16 Jun 2023filed 16 Jun 2023 | Prometheus Biosciences | SEC FORM 4 Code D | —14,000 | filing |
| 1 Jun 2023filed 2 Jun 2023 | Prometheus Biosciences | SEC FORM 4 Code J | —14,000 at $0.00 | filing |
| 1 Jun 2023filed 2 Jun 2023 | Prometheus Biosciences | SEC FORM 4 Code J | —14,000 at $0.00 | filing |
| 25 May 2023filed 30 May 2023 | PHAT Phathom Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 25 May 2023filed 30 May 2023 | PHAT Phathom PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —9,000 at $0.00 | filing |
| 9 Dec 2022filed 13 Dec 2022 | Prometheus Biosciencesoption or derivative | SEC FORM 4 Code A | —34,085 at $0.00 | filing |
| 9 Dec 2022filed 13 Dec 2022 | Prometheus Biosciences | SEC FORM 4 Code A | —9,811 at $0.00 | filing |
| 25 May 2022filed 27 May 2022 | PHAT Phathom Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.